drugset / Trial / NCT06677957
A Clinical Trial to Investigate the Clinical Drug-Drug Interaction of Divarasib With Probe Substrates of P-Glycoprotein and Breast Cancer Resistance Protein in Healthy Participants
RandomizedCrossoverOpen-labelBasic science
Summary
This is a Phase 1, open-label, two-period, one-sequence, crossover drug-drug interaction study to assess the P-gp and BCRP inhibition potential of divarasib using digoxin and rosuvastatin as probe substrates, respectively, in healthy participants.
Timeline
- Start
- 2024-11-06
- Primary completion
- 2024-12-30
- Completion
- 2024-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Digoxin | Other / unclassified | — | Oral |
| Subject | Divarasib | Small molecule | — | — |
| Subject | Rosuvastatin | Small molecule | — | Oral |
Indications
No indication recorded.